Share Price and Basic Stock Data
Last Updated: December 27, 2025, 8:34 pm
| PEG Ratio | -1.75 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chemcon Speciality Chemicals Ltd operates within the specialty chemicals sector, focusing on niche markets with significant growth potential. In the fiscal year ending March 2023, the company reported sales of ₹303 Cr, a substantial increase from ₹257 Cr in the previous fiscal year. However, the trailing twelve months (TTM) revenue stood at ₹217 Cr, indicating some fluctuation in revenue generation. Quarterly sales have shown variability, with the highest quarterly sales reported at ₹89.41 Cr in June 2022, declining to ₹52.98 Cr by December 2023. This downward trend in sales is concerning, particularly as the company heads towards FY 2025, with expectations of further revenue decline to ₹207 Cr. The company’s ability to stabilize its revenue amidst these fluctuations will be critical for long-term sustainability.
Profitability and Efficiency Metrics
Chemcon’s profitability metrics reveal a mixed performance trajectory. The operating profit margin (OPM) was recorded at 14.52% for the latest fiscal year, reflecting a notable decline from 32% in FY 2022. This reduction is indicative of rising operational costs which have outpaced revenue growth. The company reported a net profit of ₹55 Cr in FY 2023, but this figure is projected to drop to ₹24 Cr in FY 2025. The interest coverage ratio (ICR) is strong at 13.50x, suggesting that Chemcon can comfortably meet its interest obligations, while the return on equity (ROE) stood at 5%, which is below the typical sector average, indicating lower profitability relative to shareholder equity. The cash conversion cycle, recorded at 303 days, reflects inefficiencies in managing working capital, which may hinder overall profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Chemcon Speciality Chemicals Ltd exhibits robustness, characterized by zero borrowings, which positions the company favorably in terms of financial leverage. Reserves have steadily increased to ₹476 Cr, reflecting a strong retention of earnings. The current ratio is notably high at 6.69x, indicating solid liquidity and a strong ability to cover short-term liabilities. However, the total debt to equity ratio stands at 0.04, reaffirming the absence of debt. The price-to-book value (P/BV) ratio is at 1.21x, suggesting that the stock is trading close to its book value, which may present an attractive entry point for value investors. Despite these strengths, the low ROCE of 7.01% indicates that the company is not effectively utilizing its capital to generate returns, potentially limiting growth opportunities.
Shareholding Pattern and Investor Confidence
Chemcon’s shareholding structure displays significant promoter confidence, with promoters holding 74.47% of the total equity. This indicates a strong alignment of interests between the management and shareholders. However, foreign institutional investors (FIIs) have a minimal stake of only 0.27%, suggesting limited international interest in the company. Domestic institutional investors (DIIs) hold no stake, which may indicate a lack of confidence from larger domestic funds. The number of shareholders has declined to 69,211 from 86,831 over the past year, which could point to waning interest from retail investors. The stability in promoter holding suggests confidence from the management, but the lack of broader institutional interest may be a red flag for future capital inflows and market perception.
Outlook, Risks, and Final Insight
The outlook for Chemcon Speciality Chemicals Ltd hinges on its ability to stabilize revenue and improve operational efficiency. The declining sales trend and reduced profitability metrics raise concerns about the company’s competitive positioning within the specialty chemicals sector. Risks include potential market volatility, operational inefficiencies reflected in the prolonged cash conversion cycle, and the absence of debt might limit growth opportunities through leveraged investments. On the positive side, the strong liquidity position and significant promoter holding provide a safety net for investors. If the company can implement effective strategies to enhance its operational efficiency and revenue generation, it may reverse the current trend. However, failure to address these challenges could lead to continued declines in profitability and investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 393 Cr. | 42.8 | 83.5/41.2 | 24.4 | 20.5 | 0.94 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 30.8 Cr. | 62.8 | 91.9/56.0 | 14.8 | 89.6 | 1.59 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 50.2 Cr. | 738 | 932/600 | 23.1 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,385 Cr. | 74.7 | 111/74.0 | 22.4 | 22.0 | 0.67 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 643 Cr. | 258 | 393/241 | 23.1 | 93.8 | 0.97 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,820.00 Cr | 725.64 | 70.22 | 183.02 | 0.44% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 89.41 | 57.92 | 76.47 | 79.08 | 79.33 | 75.19 | 52.98 | 59.59 | 45.52 | 52.60 | 54.39 | 54.89 | 53.52 |
| Expenses | 55.86 | 48.33 | 62.98 | 65.02 | 71.62 | 66.86 | 46.64 | 55.21 | 38.40 | 44.09 | 43.10 | 49.10 | 45.75 |
| Operating Profit | 33.55 | 9.59 | 13.49 | 14.06 | 7.71 | 8.33 | 6.34 | 4.38 | 7.12 | 8.51 | 11.29 | 5.79 | 7.77 |
| OPM % | 37.52% | 16.56% | 17.64% | 17.78% | 9.72% | 11.08% | 11.97% | 7.35% | 15.64% | 16.18% | 20.76% | 10.55% | 14.52% |
| Other Income | 2.68 | 3.29 | 4.46 | 2.89 | 3.59 | 3.03 | 3.34 | 3.34 | 3.76 | 3.50 | 4.01 | 3.18 | 3.72 |
| Interest | 0.16 | 0.25 | 0.59 | 0.49 | 0.68 | 0.73 | 1.04 | 1.05 | 0.99 | 0.93 | 0.74 | 0.84 | 0.34 |
| Depreciation | 1.93 | 2.05 | 2.14 | 2.26 | 2.62 | 2.59 | 2.58 | 2.51 | 2.53 | 2.55 | 2.71 | 2.73 | 2.72 |
| Profit before tax | 34.14 | 10.58 | 15.22 | 14.20 | 8.00 | 8.04 | 6.06 | 4.16 | 7.36 | 8.53 | 11.85 | 5.40 | 8.43 |
| Tax % | 25.42% | 25.99% | 25.36% | 26.27% | 26.25% | 26.12% | 26.73% | 30.05% | 27.17% | 25.79% | 25.74% | 26.85% | 24.20% |
| Net Profit | 25.46 | 7.82 | 11.36 | 10.47 | 5.91 | 5.94 | 4.44 | 2.90 | 5.37 | 6.33 | 8.81 | 3.95 | 6.39 |
| EPS in Rs | 6.95 | 2.13 | 3.10 | 2.86 | 1.61 | 1.62 | 1.21 | 0.79 | 1.47 | 1.73 | 2.41 | 1.08 | 1.74 |
Last Updated: August 20, 2025, 12:15 pm
Below is a detailed analysis of the quarterly data for Chemcon Speciality Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 53.52 Cr.. The value appears to be declining and may need further review. It has decreased from 54.89 Cr. (Mar 2025) to 53.52 Cr., marking a decrease of 1.37 Cr..
- For Expenses, as of Jun 2025, the value is 45.75 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 49.10 Cr. (Mar 2025) to 45.75 Cr., marking a decrease of 3.35 Cr..
- For Operating Profit, as of Jun 2025, the value is 7.77 Cr.. The value appears strong and on an upward trend. It has increased from 5.79 Cr. (Mar 2025) to 7.77 Cr., marking an increase of 1.98 Cr..
- For OPM %, as of Jun 2025, the value is 14.52%. The value appears strong and on an upward trend. It has increased from 10.55% (Mar 2025) to 14.52%, marking an increase of 3.97%.
- For Other Income, as of Jun 2025, the value is 3.72 Cr.. The value appears strong and on an upward trend. It has increased from 3.18 Cr. (Mar 2025) to 3.72 Cr., marking an increase of 0.54 Cr..
- For Interest, as of Jun 2025, the value is 0.34 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.84 Cr. (Mar 2025) to 0.34 Cr., marking a decrease of 0.50 Cr..
- For Depreciation, as of Jun 2025, the value is 2.72 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.73 Cr. (Mar 2025) to 2.72 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 8.43 Cr.. The value appears strong and on an upward trend. It has increased from 5.40 Cr. (Mar 2025) to 8.43 Cr., marking an increase of 3.03 Cr..
- For Tax %, as of Jun 2025, the value is 24.20%. The value appears to be improving (decreasing) as expected. It has decreased from 26.85% (Mar 2025) to 24.20%, marking a decrease of 2.65%.
- For Net Profit, as of Jun 2025, the value is 6.39 Cr.. The value appears strong and on an upward trend. It has increased from 3.95 Cr. (Mar 2025) to 6.39 Cr., marking an increase of 2.44 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.74. The value appears strong and on an upward trend. It has increased from 1.08 (Mar 2025) to 1.74, marking an increase of 0.66.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:30 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 53 | 63 | 97 | 88 | 158 | 303 | 262 | 243 | 257 | 303 | 267 | 207 | 217 |
| Expenses | 46 | 56 | 87 | 79 | 112 | 237 | 192 | 162 | 175 | 232 | 240 | 174 | 185 |
| Operating Profit | 6 | 8 | 10 | 9 | 46 | 66 | 70 | 81 | 82 | 71 | 27 | 33 | 32 |
| OPM % | 12% | 12% | 10% | 10% | 29% | 22% | 27% | 33% | 32% | 23% | 10% | 16% | 15% |
| Other Income | 0 | -1 | 0 | 0 | 0 | 2 | 4 | 5 | 9 | 13 | 13 | 14 | 15 |
| Interest | 2 | 2 | 3 | 2 | 3 | 4 | 5 | 4 | 1 | 1 | 4 | 3 | 2 |
| Depreciation | 1 | 2 | 2 | 2 | 2 | 3 | 5 | 6 | 6 | 8 | 10 | 11 | 11 |
| Profit before tax | 3 | 3 | 5 | 5 | 41 | 61 | 65 | 76 | 84 | 74 | 26 | 33 | 34 |
| Tax % | 60% | 3% | 35% | 37% | 35% | 30% | 25% | 26% | 25% | 26% | 27% | 26% | |
| Net Profit | 1 | 3 | 3 | 3 | 26 | 43 | 49 | 56 | 63 | 55 | 19 | 24 | 25 |
| EPS in Rs | 1.46 | 3.35 | 4.09 | 3.78 | 33.21 | 13.54 | 15.37 | 15.40 | 17.13 | 15.04 | 5.24 | 6.67 | 6.80 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 27% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 200.00% | 0.00% | 0.00% | 766.67% | 65.38% | 13.95% | 14.29% | 12.50% | -12.70% | -65.45% | 26.32% |
| Change in YoY Net Profit Growth (%) | 0.00% | -200.00% | 0.00% | 766.67% | -701.28% | -51.43% | 0.33% | -1.79% | -25.20% | -52.76% | 91.77% |
Chemcon Speciality Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | -5% |
| 3 Years: | -7% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | -13% |
| 3 Years: | -27% |
| TTM: | 37% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -21% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 11% |
| 3 Years: | 7% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 1:55 am
Balance Sheet
Last Updated: December 10, 2025, 2:31 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 32 | 32 | 37 | 37 | 37 | 37 | 37 | 37 |
| Reserves | 11 | 13 | 16 | 19 | 46 | 65 | 115 | 317 | 381 | 421 | 440 | 464 | 476 |
| Borrowings | 14 | 12 | 13 | 20 | 17 | 33 | 46 | 6 | 36 | 64 | 43 | 25 | 0 |
| Other Liabilities | 12 | 10 | 9 | 15 | 27 | 43 | 34 | 44 | 45 | 32 | 26 | 29 | 35 |
| Total Liabilities | 45 | 44 | 46 | 63 | 97 | 173 | 226 | 404 | 498 | 553 | 545 | 554 | 548 |
| Fixed Assets | 20 | 20 | 19 | 24 | 30 | 40 | 49 | 67 | 82 | 141 | 146 | 149 | 144 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 9 | 34 | 14 | 42 | 40 | 47 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 11 |
| Other Assets | 25 | 24 | 27 | 38 | 67 | 133 | 173 | 328 | 382 | 398 | 356 | 355 | 346 |
| Total Assets | 45 | 44 | 46 | 63 | 97 | 173 | 226 | 404 | 498 | 553 | 545 | 554 | 548 |
Below is a detailed analysis of the balance sheet data for Chemcon Speciality Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 37.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 37.00 Cr..
- For Reserves, as of Sep 2025, the value is 476.00 Cr.. The value appears strong and on an upward trend. It has increased from 464.00 Cr. (Mar 2025) to 476.00 Cr., marking an increase of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 25.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 25.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 35.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 6.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 548.00 Cr.. The value appears to be improving (decreasing). It has decreased from 554.00 Cr. (Mar 2025) to 548.00 Cr., marking a decrease of 6.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 144.00 Cr.. The value appears to be declining and may need further review. It has decreased from 149.00 Cr. (Mar 2025) to 144.00 Cr., marking a decrease of 5.00 Cr..
- For CWIP, as of Sep 2025, the value is 47.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Mar 2025) to 47.00 Cr., marking an increase of 7.00 Cr..
- For Investments, as of Sep 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 346.00 Cr.. The value appears to be declining and may need further review. It has decreased from 355.00 Cr. (Mar 2025) to 346.00 Cr., marking a decrease of 9.00 Cr..
- For Total Assets, as of Sep 2025, the value is 548.00 Cr.. The value appears to be declining and may need further review. It has decreased from 554.00 Cr. (Mar 2025) to 548.00 Cr., marking a decrease of 6.00 Cr..
Notably, the Reserves (476.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -8.00 | -4.00 | -3.00 | -11.00 | 29.00 | 33.00 | 24.00 | 75.00 | 46.00 | 7.00 | -16.00 | 8.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 40 | 52 | 51 | 93 | 68 | 77 | 124 | 142 | 146 | 81 | 112 | 91 |
| Inventory Days | 146 | 74 | 45 | 58 | 99 | 91 | 118 | 175 | 102 | 164 | 119 | 261 |
| Days Payable | 97 | 79 | 39 | 81 | 82 | 57 | 63 | 67 | 70 | 44 | 23 | 49 |
| Cash Conversion Cycle | 89 | 47 | 57 | 70 | 86 | 111 | 179 | 250 | 177 | 201 | 208 | 303 |
| Working Capital Days | 85 | 64 | 59 | 8 | 61 | 59 | 135 | 184 | 105 | 108 | 162 | 211 |
| ROCE % | 17% | 17% | 22% | 16% | 74% | 65% | 43% | 29% | 21% | 15% | 6% | 7% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Tata Resources & Energy Fund | 100,000 | 0.27 | 2.67 | 100,000 | 2025-04-22 17:25:38 | 0% |
| Tata Resources & Energy Fund - Direct Plan | 100,000 | 0.27 | 2.67 | 100,000 | 2025-04-22 17:25:38 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 6.68 | 5.24 | 15.04 | 17.13 | 16.48 |
| Diluted EPS (Rs.) | 6.68 | 5.24 | 15.04 | 17.13 | 16.48 |
| Cash EPS (Rs.) | 9.54 | 8.05 | 17.33 | 18.84 | 17.06 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 136.68 | 130.06 | 124.86 | 113.89 | 96.56 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 136.68 | 130.06 | 124.86 | 113.89 | 96.56 |
| Dividend / Share (Rs.) | 0.00 | 0.00 | 4.00 | 4.00 | 0.00 |
| Revenue From Operations / Share (Rs.) | 56.62 | 72.91 | 82.69 | 70.19 | 66.47 |
| PBDIT / Share (Rs.) | 12.87 | 10.94 | 22.93 | 24.80 | 23.41 |
| PBIT / Share (Rs.) | 10.00 | 8.12 | 20.65 | 23.09 | 21.75 |
| PBT / Share (Rs.) | 9.05 | 7.17 | 20.24 | 22.93 | 20.76 |
| Net Profit / Share (Rs.) | 6.67 | 5.24 | 15.04 | 17.13 | 15.40 |
| PBDIT Margin (%) | 22.73 | 15.00 | 27.73 | 35.32 | 35.22 |
| PBIT Margin (%) | 17.66 | 11.14 | 24.97 | 32.89 | 32.72 |
| PBT Margin (%) | 15.98 | 9.83 | 24.48 | 32.66 | 31.23 |
| Net Profit Margin (%) | 11.78 | 7.18 | 18.19 | 24.40 | 23.16 |
| Return on Networth / Equity (%) | 4.88 | 4.02 | 12.04 | 15.04 | 15.94 |
| Return on Capital Employeed (%) | 7.23 | 6.17 | 16.36 | 20.11 | 22.23 |
| Return On Assets (%) | 4.41 | 3.52 | 9.95 | 12.60 | 13.97 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.04 | 0.08 | 0.13 | 0.08 | 0.01 |
| Asset Turnover Ratio (%) | 0.37 | 0.48 | 0.57 | 0.57 | 0.77 |
| Current Ratio (X) | 6.69 | 5.54 | 3.41 | 4.84 | 6.30 |
| Quick Ratio (X) | 4.88 | 4.58 | 2.55 | 4.40 | 4.99 |
| Inventory Turnover Ratio (X) | 2.81 | 2.90 | 3.30 | 2.49 | 2.11 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 26.58 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 23.08 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 73.42 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 76.92 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 13.50 | 11.46 | 56.44 | 159.53 | 23.61 |
| Interest Coverage Ratio (Post Tax) (X) | 8.00 | 6.49 | 38.02 | 111.22 | 16.52 |
| Enterprise Value (Cr.) | 488.86 | 718.52 | 773.10 | 787.64 | 1372.68 |
| EV / Net Operating Revenue (X) | 2.36 | 2.69 | 2.55 | 3.06 | 5.64 |
| EV / EBITDA (X) | 10.37 | 17.93 | 9.20 | 8.67 | 16.00 |
| MarketCap / Net Operating Revenue (X) | 2.92 | 3.17 | 2.77 | 3.80 | 6.13 |
| Retention Ratios (%) | 0.00 | 0.00 | 73.41 | 0.00 | 0.00 |
| Price / BV (X) | 1.21 | 1.78 | 1.84 | 2.34 | 4.22 |
| Price / Net Operating Revenue (X) | 2.92 | 3.17 | 2.77 | 3.80 | 6.13 |
| EarningsYield | 0.04 | 0.02 | 0.06 | 0.06 | 0.03 |
After reviewing the key financial ratios for Chemcon Speciality Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 6.68. This value is within the healthy range. It has increased from 5.24 (Mar 24) to 6.68, marking an increase of 1.44.
- For Diluted EPS (Rs.), as of Mar 25, the value is 6.68. This value is within the healthy range. It has increased from 5.24 (Mar 24) to 6.68, marking an increase of 1.44.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.54. This value is within the healthy range. It has increased from 8.05 (Mar 24) to 9.54, marking an increase of 1.49.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 136.68. It has increased from 130.06 (Mar 24) to 136.68, marking an increase of 6.62.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 136.68. It has increased from 130.06 (Mar 24) to 136.68, marking an increase of 6.62.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 56.62. It has decreased from 72.91 (Mar 24) to 56.62, marking a decrease of 16.29.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 12.87. This value is within the healthy range. It has increased from 10.94 (Mar 24) to 12.87, marking an increase of 1.93.
- For PBIT / Share (Rs.), as of Mar 25, the value is 10.00. This value is within the healthy range. It has increased from 8.12 (Mar 24) to 10.00, marking an increase of 1.88.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.05. This value is within the healthy range. It has increased from 7.17 (Mar 24) to 9.05, marking an increase of 1.88.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 6.67. This value is within the healthy range. It has increased from 5.24 (Mar 24) to 6.67, marking an increase of 1.43.
- For PBDIT Margin (%), as of Mar 25, the value is 22.73. This value is within the healthy range. It has increased from 15.00 (Mar 24) to 22.73, marking an increase of 7.73.
- For PBIT Margin (%), as of Mar 25, the value is 17.66. This value is within the healthy range. It has increased from 11.14 (Mar 24) to 17.66, marking an increase of 6.52.
- For PBT Margin (%), as of Mar 25, the value is 15.98. This value is within the healthy range. It has increased from 9.83 (Mar 24) to 15.98, marking an increase of 6.15.
- For Net Profit Margin (%), as of Mar 25, the value is 11.78. This value exceeds the healthy maximum of 10. It has increased from 7.18 (Mar 24) to 11.78, marking an increase of 4.60.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.88. This value is below the healthy minimum of 15. It has increased from 4.02 (Mar 24) to 4.88, marking an increase of 0.86.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.23. This value is below the healthy minimum of 10. It has increased from 6.17 (Mar 24) to 7.23, marking an increase of 1.06.
- For Return On Assets (%), as of Mar 25, the value is 4.41. This value is below the healthy minimum of 5. It has increased from 3.52 (Mar 24) to 4.41, marking an increase of 0.89.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.04. This value is within the healthy range. It has decreased from 0.08 (Mar 24) to 0.04, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.37. It has decreased from 0.48 (Mar 24) to 0.37, marking a decrease of 0.11.
- For Current Ratio (X), as of Mar 25, the value is 6.69. This value exceeds the healthy maximum of 3. It has increased from 5.54 (Mar 24) to 6.69, marking an increase of 1.15.
- For Quick Ratio (X), as of Mar 25, the value is 4.88. This value exceeds the healthy maximum of 2. It has increased from 4.58 (Mar 24) to 4.88, marking an increase of 0.30.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.81. This value is below the healthy minimum of 4. It has decreased from 2.90 (Mar 24) to 2.81, marking a decrease of 0.09.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 13.50. This value is within the healthy range. It has increased from 11.46 (Mar 24) to 13.50, marking an increase of 2.04.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.00. This value is within the healthy range. It has increased from 6.49 (Mar 24) to 8.00, marking an increase of 1.51.
- For Enterprise Value (Cr.), as of Mar 25, the value is 488.86. It has decreased from 718.52 (Mar 24) to 488.86, marking a decrease of 229.66.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.36. This value is within the healthy range. It has decreased from 2.69 (Mar 24) to 2.36, marking a decrease of 0.33.
- For EV / EBITDA (X), as of Mar 25, the value is 10.37. This value is within the healthy range. It has decreased from 17.93 (Mar 24) to 10.37, marking a decrease of 7.56.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.92. This value is within the healthy range. It has decreased from 3.17 (Mar 24) to 2.92, marking a decrease of 0.25.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 1.21. This value is within the healthy range. It has decreased from 1.78 (Mar 24) to 1.21, marking a decrease of 0.57.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.92. This value is within the healthy range. It has decreased from 3.17 (Mar 24) to 2.92, marking a decrease of 0.25.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemcon Speciality Chemicals Ltd:
- Net Profit Margin: 11.78%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.23% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.88% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.88
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 29.5 (Industry average Stock P/E: 70.22)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.04
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.78%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Block No 355, Manjusar Kinpad Road, Vadodra Gujarat 391775 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kamalkumar Rajendra Aggarwal | Chairman & Managing Director |
| Mr. Naresh Vijaykumar Goyal | Joint Managing Director |
| Mr. Rajesh Chimanlal Gandhi | WholeTime Director & CFO |
| Mr. Himanshu Prafulchandra Purohit | Whole Time Director |
| Mr. Navdeep Naresh Goyal | Whole Time Director |
| Mr. Rajveer Kamal Aggarwal | Non Exe.Non Ind.Director |
| Mr. Bharat Chunilal Shah | Independent Director |
| Mrs. Neelu Atulkumar Shah | Independent Director |
| Mr. Lalit Ramniklal Mehta | Independent Director |
| Mr. Pankaj Amritlal Shah | Independent Director |
| Mr. Ketan Bhailal Shah | Independent Director |
| Mr. Neel Snehalkumar Shah | Independent Director |
FAQ
What is the intrinsic value of Chemcon Speciality Chemicals Ltd?
Chemcon Speciality Chemicals Ltd's intrinsic value (as of 28 December 2025) is 168.50 which is 16.17% lower the current market price of 201.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 735 Cr. market cap, FY2025-2026 high/low of 295/160, reserves of ₹476 Cr, and liabilities of 548 Cr.
What is the Market Cap of Chemcon Speciality Chemicals Ltd?
The Market Cap of Chemcon Speciality Chemicals Ltd is 735 Cr..
What is the current Stock Price of Chemcon Speciality Chemicals Ltd as on 28 December 2025?
The current stock price of Chemcon Speciality Chemicals Ltd as on 28 December 2025 is 201.
What is the High / Low of Chemcon Speciality Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemcon Speciality Chemicals Ltd stocks is 295/160.
What is the Stock P/E of Chemcon Speciality Chemicals Ltd?
The Stock P/E of Chemcon Speciality Chemicals Ltd is 29.5.
What is the Book Value of Chemcon Speciality Chemicals Ltd?
The Book Value of Chemcon Speciality Chemicals Ltd is 140.
What is the Dividend Yield of Chemcon Speciality Chemicals Ltd?
The Dividend Yield of Chemcon Speciality Chemicals Ltd is 0.00 %.
What is the ROCE of Chemcon Speciality Chemicals Ltd?
The ROCE of Chemcon Speciality Chemicals Ltd is 7.01 %.
What is the ROE of Chemcon Speciality Chemicals Ltd?
The ROE of Chemcon Speciality Chemicals Ltd is 5.00 %.
What is the Face Value of Chemcon Speciality Chemicals Ltd?
The Face Value of Chemcon Speciality Chemicals Ltd is 10.0.